Recently, the National Health and Family Planning Commission (NHFPC) Medical and Health Science and Technology Development Research Center officially issued the "Notification of 2018 Projects for Major New Drug Creation" to enterprises that have received project support. CGeneTech's "Research and development of ESP-8012, a new hypoglycemic dipeptidyl peptidase inhibitor (chemical 1)" was awarded the project support of the National Major New Drug Creation Project during the 13th Five-Year Plan period, and received the first installment of 2018 central financial support. The project has been successfully included in the national level of innovative drug priority support track.

During the "13th Five-Year Plan" period, the "Major New Drug Creation" Science and Technology Major Project mainly focuses on malignant tumors, cardiovascular and cerebrovascular diseases, drug-resistant pathogenic infections, viral infections and other major diseases, with a focus on supporting original drugs with independent intellectual property rights, high clinical value, good market prospects, and in the preclinical and clinical research stages. Based on the long-term development needs, actively translate and apply the latest achievements of basic research related to new drug development at home and abroad, and carry out innovative drug discovery research based on new targets and new mechanisms of action. Drug discovery research.

China is a major diabetic country with more than 100 million diabetic patients, ranking first in the world. CGeneTech (Suzhou, China) Co., Ltd. was approved by the State Food and Drug Administration of China in May 2017 for the clinical trial of Shengliptin phosphate, a Class 1 innovative drug for the treatment of type 2 diabetes. At present, CGeneTech has reached an agreement with institutions including Jiangsu Provincial People's Hospital to conduct the phase I clinical trial of Shenggliptin phosphate. Centagliptin phosphate belongs to the dipeptidyl peptidase (DPP)-4 inhibitor class, which has the greatest advantage of not causing hypoglycemia and weight gain, and has cardiovascular protection; at the same time, Chinese patients with type 2 diabetes are more severely damaged by pancreatic β-cells than those in Europe and the United States, and one of the characteristics of DPP-4 inhibitors is that they can improve β-cell damage, thus Chinese patients can benefit more. This has led to the increasing acceptance of DPP-4 inhibitors by physicians in China.

With a team of elites in the biopharmaceutical industry, CGeneTech has developed a new class 1 glucose-lowering drug, Centagliptin, to bring new hope to the 114 million diabetes patients in China. When compared with the best glucose-lowering drugs in the world, Shengliptin outperforms its competitors in terms of efficacy, safety and cost of administration, and is expected to be the first independently developed new diabetes drug approved for marketing in China.